O SlideShare utiliza cookies para otimizar a funcionalidade e o desempenho do site, assim como para apresentar publicidade mais relevante aos nossos usuários. Se você continuar a navegar o site, você aceita o uso de cookies. Leia nosso Contrato do Usuário e nossa Política de Privacidade.
O SlideShare utiliza cookies para otimizar a funcionalidade e o desempenho do site, assim como para apresentar publicidade mais relevante aos nossos usuários. Se você continuar a utilizar o site, você aceita o uso de cookies. Leia nossa Política de Privacidade e nosso Contrato do Usuário para obter mais detalhes.
Rongene Pharma is a global pharmaceutical firm launching the innovative drug discovery platform. Our platform assists our clients with customized lead compounds and preclinical drug candidates. Our clients include pharmaceutical, biotech companies, research institutes, universities, and governmental organizations etc. Rongene also provides a comprehensive portfolio of services in early stage drug design, discovery and development in an efficient and cost-effective manner. http://www.rongene.com
Integrated Drug DiscoveryDedicated to Novel Drug Candidates for our CustomersOverview Target AnalysisRongene is a global pharmaceutical firm launching the innovative drugdiscovery platform. Our platform assists our clients with customizedlead compounds and preclinical drug candidates. Our clients includepharmaceutical, biotech companies, research institutes, universities, Target Screeningand governmental organizations etc. Rongene also provides acomprehensive portfolio of services in early stage drug discovery anddevelopment in an efficient and cost-effective manner. Hit EvaluationDrug Discovery PlatformOur creative platform focuses on target analysis, drug design, assaydevelopment, library screening, hit to lead, lead optimization, and Lead Optimizationpreclinical evaluation. It is seamlessly integrated with drug informationdatabase, precise and multiple target screening, druggability, ADMETindicators, bioassay, hit evaluation, zebrafish early evaluation and animal Preclinicalmodel for further development. This platform has successfully helped our Developmentclients in drug design/discovery with decades of experiences and strong trackperformance record of our team.Discovery CapabilitiesOur platform is equipped with a wide range of proprietary technologies and state-of-the-art facilities, whichconsist of commercial drug design software packages, innovative modeling algorithms and databases, highperformance computing system, multimode plate readers, microscopes, etc. The team members have alsoauthored over 200 publications in top-tier journals with over 1,500 citations, and filed over 10 drug discoverypatents and software copyrights.Service and ResearchThe tailored solutions and services for each project will be provided for drug discovery to search, evaluate,optimize the novel lead compounds and define the preclinical drug candidates through our In Silico, In Vitroand In Vivo techniques. Our scientists will be working closely with the respective customers to integrate theirspecific expertise and, where appropriate, to draw on customized research tools, solutions and materials.Discovery research is able to provide the customized lead compounds and preclinical drug candidates basedon the targets and diseases required by our clients; optimize and profile the lead structures by our definedcriteria, and identify the active ingredients and mode of action for natural products based on our discoveryplatform. 8 Dongfu Road, Suzhou Industrial Park, Suzhou, China 215123 | www.rongene.com
In Silico In Vitro In Vivo R&D Virtual Screening Assay development Zebrafish Platform Drug Discovery • molecular docking • Biochemical assay • mRNA expression marker • Lead discovery • MD simulation • Cellular assay • Anti-Angiogenesis • Preclinical drug • Free energy calculation • Neurological disorder candidate • Pharmacophore model Library screening • Cardiovascular • Primary screening • Skeletal disease Lead Optimization Structure Optimization • Secondary screening • Immunological model • QSAR analysis • Iterative screening • Toxicity test Natural Product • Similarity search • Extraction analysis • Scaffold hopping Hit to lead Animal Model • Active ingredient • Cellular selectivity • Early Tox studies identification Library Design • Cellular pharmacology • In vivo PK/PD studies* • Isolation, specification • Diverse library design • Chemical amenability • In vivo efficacy • Focused library design • IP assessment • Safety assessment* • Combinatorial design • Mode of action ADME/T Modeling ADME/T Profiling * conducted with partnersPipelineRongene discovery group has started 6 novel leads projects in oncology and cardiovascular. The team also seek thecollaboration with our customers and strategic partners with the expertise and capability who are interested toacquire and develop the early-stage drug candidates from discovery through development and commercialization.If you are interested in initiating your own early-stage drug discovery projects, and partnering in any of drugdiscovery programs, please contact us. Target Target Hit Lead Preclinical Clinical Analysis Screening Evaluation Optimization Development Trial HY-004 （cerebral hemorrhage） HY-029 （cerebral hemorrhage） HY-001 （Anticancer） HT-007 （Anticancer） ML-019 （Anti-angiogenesis） MYSL-003 （Anti-atherosclerosis） 8 Dongfu Road, Suzhou Industrial Park, Suzhou, China 215123 | www.rongene.com